APP and Cognitive impairment: In the final probe test, FGF21 administration increased the residence time in the target quadrant and the number of crossing the original location of the platform in the APP/PS1 model, suggesting that FGF21 could alleviate cognitive impairment by directly acting on the central nervous system (Figure 4D-E).